(TRNS) Transcat - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8935291075
TRNS: Calibration, Laboratory, Instruments, Services, Test, Measurement
Transcat, Inc. (NASDAQ:TRNS) is a leading provider of calibration and laboratory instrument services, operating across the United States, Canada, and internationally. The company is structured into two primary business segments: Service and Distribution, each tailored to meet the precise needs of industries where accuracy and compliance are paramount.
The Service segment is the cornerstone of Transcats operations, offering a comprehensive suite of services including calibration, repair, inspection, analytical qualification, and preventative maintenance. To enhance operational efficiency, the company has developed CalTrak, a proprietary document and asset management system. This platform streamlines workflow management for both its calibration service centers and customers assets. Additionally, Transcat provides an online customer portal known as Compliance, Control and Cost, which offers web-based asset management capabilities and secure off-site storage for calibration and service records. These tools not only improve transparency but also ensure that customers maintain regulatory compliance in their operations.
The Distribution segment focuses on the sale and rental of test, measurement, and control instruments, catering to a wide range of industries. Beyond hardware, this segment also offers value-added services such as equipment calibration and certification, rental options, used equipment sales, and equipment kitting. Transcat markets its products through a multi-channel approach, including its website, digital and print advertising, outbound sales initiatives, and an inbound call center. This diversified strategy ensures that customers have easy access to the tools they need to maintain precision and efficiency in their processes.
Transcats customer base spans highly regulated industries, with a significant focus on life sciences, including pharmaceutical, biotechnology, medical device, and other FDA-regulated sectors. The company also serves aerospace and defense, industrial manufacturing, energy and utilities, and other industries where the accuracy of equipment and processes is critical. By providing specialized services and products, Transcat plays a pivotal role in ensuring that its customers meet stringent regulatory requirements and maintain operational excellence.
Founded in 1964 and headquartered in Rochester, New York, Transcat has established itself as a trusted partner for industries requiring precision and reliability. Its commitment to innovation and customer satisfaction has positioned it as a key player in the calibration and instrument
Additional Sources for TRNS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TRNS Stock Overview
Market Cap in USD | 683m |
Sector | Industrials |
Industry | Industrial Distribution |
GiC Sub-Industry | Trading Companies & Distributors |
IPO / Inception | 1990-03-27 |
TRNS Stock Ratings
Growth 5y | 51.1% |
Fundamental | 25.2% |
Dividend | 0.0% |
Rel. Strength | -36.3 |
Analysts | 4.4/5 |
Fair Price Momentum | 69.51 USD |
Fair Price DCF | 48.16 USD |
TRNS Dividends
No Dividends PaidTRNS Growth Ratios
Growth Correlation 3m | -86.8% |
Growth Correlation 12m | -68.8% |
Growth Correlation 5y | 87% |
CAGR 5y | 23.34% |
CAGR/Max DD 5y | 0.45 |
Sharpe Ratio 12m | -0.07 |
Alpha | -38.05 |
Beta | 0.661 |
Volatility | 48.06% |
Current Volume | 74.1k |
Average Volume 20d | 61.8k |
As of April 03, 2025, the stock is trading at USD 75.36 with a total of 74,123 shares traded.
Over the past week, the price has changed by +4.89%, over one month by +0.09%, over three months by -28.95% and over the past year by -30.86%.
Neither. Based on ValueRay Fundamental Analyses, Transcat is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.24 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TRNS as of April 2025 is 69.51. This means that TRNS is currently overvalued and has a potential downside of -7.76%.
Transcat has received a consensus analysts rating of 4.40. Therefor, it is recommend to buy TRNS.
- Strong Buy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, TRNS Transcat will be worth about 77 in April 2026. The stock is currently trading at 75.36. This means that the stock has a potential upside of +2.23%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 100.2 | 32.9% |
Analysts Target Price | 121.2 | 60.8% |
ValueRay Target Price | 77 | 2.2% |